Operating costs and other operating income - Summary of R&D expenditure by program (Details) - EUR (€) € in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Operating costs and other operating income | |||
| Total R&D expenses | € (335,459) | € (241,294) | € (269,797) |
| Ziritaxestat program | |||
| Operating costs and other operating income | |||
| Total R&D expenses | (1,096) | ||
| SIKi program | |||
| Operating costs and other operating income | |||
| Total R&D expenses | (18,400) | (18,900) | (47,727) |
| TYK2 program on GLPG3667 | |||
| Operating costs and other operating income | |||
| Total R&D expenses | (34,965) | (31,289) | (24,467) |
| CAR-T programs in oncology | |||
| Operating costs and other operating income | |||
| Total R&D expenses | (170,998) | (82,218) | (29,999) |
| Other programs | |||
| Operating costs and other operating income | |||
| Total R&D expenses | € (111,096) | € (108,887) | € (166,507) |